Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Certain disease states are characterized by disturbances in production, accumulation or clearance of protein. In Alzheimer disease, accumulation of amyloid-beta (Abeta) in the brain and disease-causing mutations in amyloid precursor protein or in enzymes that produce Abeta indicate dysregulation of production or clearance of Abeta. Whether dysregulation of Abeta synthesis or clearance causes the most common form of Alzheimer disease (sporadic, >99% of cases), however, is not known. Here, we describe a method to determine the production and clearance rates of proteins within the human central nervous system (CNS). We report the first measurements of the fractional production and clearance rates of Abeta in vivo in the human CNS to be 7.6% per hour and 8.3% per hour, respectively. This method may be used to search for novel biomarkers of disease, to assess underlying differences in protein metabolism that contribute to disease and to evaluate treatments in terms of their pharmacodynamic effects on proposed disease-causing pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In non-pathological conditions the clearance of cerebral Aβ exceeds its production [9].”
From PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier (2022) · cites this paper as [9]
In the citing paper
“we adapted an in vivo stable isotopic labeling kinetics technique previously described in humans (43).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [43]
In the citing paper
“which is approximately 4-times slower than the turnover rate for the total CNS Aβ peptide (Fig. 6) [31]”
From In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS (2012) · cites this paper as [31]
In the citing paper
“The interstitial concentration of Aβ is higher in awake than in sleeping rodents and humans”
From Sleep Drives Metabolite Clearance from the Adult Brain (2013) · cites this paper as [15]
In the citing paper
“In prior SILK studies (19), plasma 13C6-leucine enrichment was found to adequately represent 13C6 labeling in the precursor pool for Aβ synthesis.”
From An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice (2014) · cites this paper as [19]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Self-citationDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“Several earlier studies have shown that some plasma Aβ can enter the CN”
BackgroundSelf-citationOccurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · cited 1×
“In Down syndrome, three copies of APP result in increased production of Aβ, and 100% of individuals with Down syndrome develop Alzheimer disease pathology by age 35 (ref”
Garlick, P. J., McNurlan, M. A., & Preedy, V. R. (1980) · Biochemical Journal · doi:10.1042/bj1920719 · Cited by 973
Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676
Cerebrospinal Fluid in Diseases of the Nervous System.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-517_1 · Cited by 657
Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains
Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618
Cited by
Items 301–400 of 627
The proteomic toolbox for studying cerebrospinal fluid
van Gool, A. J., & Hendrickson, R. C. (2012) · Expert Review of Proteomics · doi:10.1586/epr.12.6 · Cited by 27
Role of autophagy in the pathogenesis of Alzheimer disease
Kızılarslanoğlu, M. C., & Ülger, Z. (2015) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1407-75 · Cited by 24
Antonyan, A. A., Schlenzig, D., Schilling, S., Naumann, M., Sharoyan, S. G., Mardanyan, S. S., & Demuth, H. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.12.001 · Cited by 24
Pearson, A., Ajoy, R., Crynen, G., Reed, J. M., Algamal, M., Mullan, M., Purohit, D., Crawford, F., & Ojo, J. O. (2020) · BMC Neurology · doi:10.1186/s12883-020-01849-3 · Cited by 25
Rosa-Neto, P., Hsiung, G.-Y., Masellis, M., & participants, O. B. O. T. C. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt223 · Cited by 23
Li, H., Nam, Y., Salimi, A., & Lee, J. Y. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00267 · Cited by 23
The Potential Role of miRNA-Regulated Autophagy in Alzheimer’s Disease
Zhang, H., Liang, J., & Chen, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147789 · Cited by 24
Abdelghani, E., Waller, A. P., Wolfgang, K. J., Stanek, J. R., Parikh, S. V., Rovin, B. H., Smoyer, W. E., the PNRC Investigators, the NEPTUNE Investigators, & Kerlin, B. A. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000047 · Cited by 23
Lin, H.-C., Huang, C.-L., Huang, Y.-J., Hsiao, I., Chung-Wei, Y., & Chuang, C. (2016) · Toxicology in Vitro · doi:10.1016/j.tiv.2016.04.014 · Cited by 23
Alzheimer's disease and Down's syndrome: Treating two paths to dementia
Weksler, M. E., Szabo, P., Relkin, N. R., Reidenberg, M. M., Weksler, B. B., & Coppus, A. M. W. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.10.013 · Cited by 24
Li, H., Salimi, A., & Lee, J. Y. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00491 · Cited by 22
Colmant, L., Boyer, E., Gérard, T., Sleegers, K., Lhommel, R., Ivanoiu, A., Lefèvre, P., Kienlen‐Campard, P., & Hanseeuw, B. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021173 · Cited by 23
Wardlaw, S. L., Burant, C., Klein, S., Meece, K., White, A. E., Kasten, T. P., Lucey, B. P., & Bateman, R. J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4087 · Cited by 24
Self-citationMathematical Model Shows How Sleep May Affect Amyloid-β Fibrillization
Hoore, M., Khailaie, S., Montaseri, G., Mitra, T., & Meyer‐Hermann, M. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.07.011 · Cited by 25
Quantitative Measurement of Cerebrospinal Fluid Amyloid-β Species by Mass Spectrometry
Seino, Y., Nakamura, T., Harada, T., Nakahata, N., Kawarabayashi, T., Ueda, T., Takatama, M., & Shoji, M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200987 · Cited by 24
Metabolism of PLTP, CETP, and LCAT on multiple HDL sizes using the Orbitrap Fusion Lumos
Singh, S. A., Andraski, A. B., Higashi, H., Lee, L. H., Ramsaroop, A., Sacks, F. M., & Aikawa, M. (2020) · JCI Insight · doi:10.1172/jci.insight.143526 · Cited by 25
Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer’s Disease
Seripa, D., Panza, F., Paroni, G., D’Onofrio, G., Bisceglia, P., Gravina, C., Urbano, M., Lozupone, M., Solfrizzi, V., Bizzarro, A., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0547-x · Cited by 25
Elbert, D. L., Patterson, B. W., & Bateman, R. J. (2015) · Mathematical Biosciences · doi:10.1016/j.mbs.2014.11.004 · Cited by 20
Self-citationBiomarker-Driven Therapeutic Management of Alzheimer’s Disease: Establishing the Foundations
Cummings, J. L., & Zhong, K. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.205 · Cited by 22
Brzdak, P., Nowak, D., Wiera, G., & Mozrzymas, J. W. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00178 · Cited by 21
Gao, X., Ming, J., Liu, S., Lai, B., Fang, F., & Cang, J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.02.024 · Cited by 27
Murray, I. V. J., Bass, B., Upson, S., Roy, K., Montgomery, E., & Jalonen, T. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.160059 · Cited by 20
Amentoflavone Promotes Cellular Uptake and Degradation of Amyloid-Beta in Neuronal Cells
Han, B. H., Cofell, B., Everhart, E., Humpal, C., Kang, S.-S., Lee, S. K., & Kim‐Han, J. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115885 · Cited by 20
Lu, Y., Barton, H. A., Leung, L. Y., Zhang, L., Hajós‐Korcsok, É., Nolan, C. E., Liu, J., Becker, S. L., Wood, K. M., Robshaw, A., et al. (2012) · Neurodegenerative Diseases · doi:10.1159/000341217 · Cited by 21
Interactions between Beta-Amyloid and Pericytes in Alzheimer’s Disease
Li, Y.-Y., Guo, D.-D., Duan, R., & Li, Y. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2904136 · Cited by 19
Tomazela, D. M., Patterson, B. W., Hanson, E. R., Spence, K. L., Kanion, T. B., Salinger, D. H., Vicini, P., Barret, H., Heins, H. B., Cole, F. S., et al. (2010) · Analytical Chemistry · doi:10.1021/ac1001433 · Cited by 19
Alzheimer′s disease: Unique markers for diagnosis & new treatment modalities
Aggarwal, N. T., Shah, R. C., & Bennett, D. A. (2015) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.169193 · Cited by 30
Applications of Biotechnology in Neurology
Jain, K. K. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-272-8 · Cited by 25
Unbiased and targeted mass spectrometry for the HDL proteome
Singh, S. A., & Aikawa, M. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000374 · Cited by 20
Nicotine Acts on Cholinergic Signaling Mechanisms to Directly Modulate Choroid Plexus Function
Lallai, V., Grimes, N. P., Fowler, J. P., Sequeira, P. A., Cartagena, P. M., Limón, A., Coutts, M., Monuki, E. S., Bunney, W. E., Demuro, A., et al. (2019) · eNeuro · doi:10.1523/eneuro.0051-19.2019 · Cited by 19
Treatment of Alzheimer’s Disease: Current Management and Experimental Therapeutics
Honig, L. S., & Boyd, C. D. (2013) · Current Translational Geriatrics and Experimental Gerontology Reports · doi:10.1007/s13670-013-0056-3 · Cited by 21
Ito, S., Matsumiya, K., Ohtsuki, S., Kamiie, J., & Terasaki, T. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.125 · Cited by 19
Expanding the Repertoire of Biomarkers for Alzheimer’s Disease: Targeted and Non-targeted Approaches
Galasko, D. R. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00256 · Cited by 21
Mitani, Y., Yarimizu, J., Akashiba, H., Shitaka, Y., Ni, K., & Matsuoka, N. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12125 · Cited by 19
Liu, X., Wong, H. H., Scearce-Levie, K. A., Watts, R. J., Coraggio, M., Shin, Y. G., Peng, K., Wildsmith, K. R., Atwal, J. K., Mango, J., et al. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.050864 · Cited by 18
Protein accumulation in the endoplasmic reticulum as a non-equilibrium phase transition
Budrikis, Z., Costantini, G., Porta, C. A. M. L., & Zapperi, S. (2014) · Nature Communications · doi:10.1038/ncomms4620 · Cited by 19
An inorganic overview of natural Aβ fragments: Copper(II) and zinc(II)-mediated pathways
Lanza, V., Bellia, F., & Rizzarelli, E. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.04.004 · Cited by 21
Michno, W., Blennow, K., Zetterberg, H., & Brinkmalm, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15466 · Cited by 19
Alzheimer’s Disease: Current Perspectives and Advances in Physiological Modeling
Boder, E. J., & Banerjee, I. A. (2021) · Bioengineering · doi:10.3390/bioengineering8120211 · Cited by 18
Biomarkers for Alzheimer’s disease
Sonnen, J. A., Keene, C. D., Montine, K. S., Li, G., Peskind, E. R., Zhang, J., & Montine, T. J. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.8.1021 · Cited by 19
Multi-compartmental model of glymphatic clearance of solutes in brain tissue
Poulain, A., Riseth, J. N., & Vinje, V. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280501 · Cited by 19
Quartino, A. L., Huledal, G., Sparve, E., Lüttgen, M., Bueters, T., Karlsson, P., Olsson, T., Paraskos, J., Maltby, J., Claeson‐Bohnstedt, K., et al. (2014) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.130 · Cited by 18
Protein Turnover Measurements in Human Serum by Serial Immunoaffinity LC-MS/MS
Farrokhi, V., Chen, X., & Neubert, H. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.272922 · Cited by 17
Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
Cuthbert, J. J., Pellicori, P., & Clark, A. L. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s234772 · Cited by 18
Amyloid –β pathology in Alzheimer’s disease: A nano delivery approach
Meghana, G. S., Gowda, D., Chidambaram, S. B., & Osmani, R. A. M. (2023) · Vibrational Spectroscopy · doi:10.1016/j.vibspec.2023.103510 · Cited by 17
Weihl, C. C. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0180-y · Cited by 17
Abdul‐Hay, S. O., Edirisinghe, P. D., & Thatcher, G. R. J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06355.x · Cited by 18
Alzheimer's Disease Diagnosis Using Misfolding Proteins in Blood
Lee, H., Ugay, D. A., Hong, S., & Kim, Y. S. (2020) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2020.19.1.1 · Cited by 17
Morgado, B., Klafki, H., Bauer, C., Waniek, K., Esselmann, H., Wirths, O., Hansen, N., Lachmann, I., Osterloh, D., Schuchhardt, J., et al. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01751-2 · Cited by 17
Evolution of lipid nanoparticles as charioteers of Alzheimer's disease therapeutics
Chakraborty, B., Patel, G., Padhan, B., Das, J., & Patel, M. (2024) · Applied Materials Today · doi:10.1016/j.apmt.2024.102442 · Cited by 18
Clinical trial methodologies for disease-modifying therapeutic approaches
Aisen, P. S. S. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.008 · Cited by 16
Cerebral Aβ 40 and systemic hypertension
Tayler, H. M., Palmer, J. C., Thomas, T. L., Kehoe, P. G., Paton, J. F. R., & Love, S. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17724930 · Cited by 17
Elbert, D. L., Mawuenyega, K. G., Scott, E. A., Wildsmith, K. R., & Bateman, R. J. (2008) · Journal of Proteome Research · doi:10.1021/pr800386u · Cited by 16
Self-citationLehmann, S., Schraen‐Maschke, S., Buée, L., Vidal, J., Delaby, C., Hirtz, C., Blanc, F., Paquet, C., Allinquant, B., Bombois, S., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00755-3 · Cited by 15
Chan, H. H., Koh, R. Y., Lim, C. L., & Leong, C. O. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666191023102422 · Cited by 15
Computational modeling of the effects of autophagy on amyloid-β peptide levels
Han, K., Kim, S. H., & Choi, M. Y. (2020) · Theoretical Biology and Medical Modelling · doi:10.1186/s12976-020-00119-6 · Cited by 16
Mechanisms of amyloid-β34 generation indicate a pivotal role for BACE1 in amyloid homeostasis
Ulku, I., Liebsch, F., Åkerman, S., Schulz, J. F., Kulic, L., Höck, C., Pietrzik, C. U., Spiezio, A. D., Thinakaran, G., Säftig, P., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-28846-z · Cited by 16
Song, S., Wu, J., Cheng, Y., Ma, L., Liu, T., Liu, J., Liu, J., Sotor, J. Z., & Luan, P. (2021) · Applied Materials Today · doi:10.1016/j.apmt.2021.101028 · Cited by 16
A Two-Dimensional Approach to Study Amyloid β-Peptide Fragment (25−35)
Triulzi, R. C., Li, C., Naistat, D. M., Orbulescu, J., & Leblanc, R. M. (2007) · The Journal of Physical Chemistry C · doi:10.1021/jp0669005 · Cited by 15
Novel strategies for the prevention of dementia from Alzheimer's disease
Shineman, D. W., & Fillit, H. M. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/dwshineman · Cited by 15
Topalis, V., Voros, C., & Ziaka, M. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251361578 · Cited by 16
Yang, Q., Yang, C., Lv, H., Zheng, X., Mao, S., Liu, N., Mo, S., Liao, B., Yang, M., Lü, Z., et al. (2024) · Inflammation · doi:10.1007/s10753-024-02043-0 · Cited by 15
The Role of Aging in Alzheimer’s Disease
Kerchner, G. A., & Wyss‐Coray, T. (2015) · Springer eBooks · doi:10.1007/978-3-319-23246-1_7 · Cited by 17
The clinical utility of mass spectrometry based protein assays
Lassman, M. E., McAvoy, T., Chappell, D. L., Lee, A. Y., Zhao, X., & Laterza, O. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.05.027 · Cited by 15
Posadas, Y., Parra-Ojeda, L., Perez‐Cruz, C., & Quintanar, L. (2021) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.1c00846 · Cited by 14
Brackhan, M., Calza, G., Lundgren, K., Bascuñana, P., Brüning, T., Soliymani, R., Kumar, R., Abelein, A., Baumann, M., Lalowski, M. M., et al. (2022) · EMBO Reports · doi:10.15252/embr.202154405 · Cited by 14
Assessment of Serum Protein Dynamics by Native SILAC Flooding (SILflood)
Nolte, H., Hölper, S., Selbach, M., Braun, T. W., & Krüger, M. (2014) · Analytical Chemistry · doi:10.1021/ac502883p · Cited by 14
Singhaarachchi, P. H., Antal, P., Calon, F., Culmsee, C., Delpech, J.-C., Feldotto, M., Geertsema, J., Hoeksema, E. E., Kőrösi, A., Layé, S., et al. (2025) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2025.102821 · Cited by 13
LRP1 at the crossroads of Aβ clearance and therapeutic targeting in Alzheimer’s disease
Deng, Y., Yin, H., Lu, Z., Lan, H., Liu, W., Zuo, C., Pan, N., Tian, X., & Gong, Q. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1669405 · Cited by 16
Vascular Function and Ion Channels in Alzheimer's Disease
Taylor, J. L., Baudel, M. A. S. M., Nieves‐Cintrón, M., & Navedo, M. F. (2024) · Microcirculation · doi:10.1111/micc.12881 · Cited by 15
Janssen, L., Dubbelaar, M. L., Holtman, I. R., de Boer-Bergsma, J. J., Eggen, B. J. L., Boddeke, H. W. G. M., Deyn, P. P. D., & Dam, D. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.11.014 · Cited by 14
Daurio, N. A., Wang, S.-P., Chen, Y., Zhou, H., McLaren, D. G., Roddy, T. P., Johns, D. G., Milot, D. P., Kasumov, T., Erion, M. D., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.241091 · Cited by 13
Fluids and flows in brain cancer and neurological disorders
Jin, P., & Munson, J. M. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1582 · Cited by 15
Alhodieb, F. S., Rahman, M. A., Barkat, M. A., Alanezi, A. A., Barkat, H. A., Hadi, H. A., Harwansh, R. K., & Mittal, V. (2023) · Nanomedicine · doi:10.2217/nnm-2022-0108 · Cited by 13
Lantz, M. J., Roberts, A. M., Delgado, D. D., & Nichols, R. A. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02807-9 · Cited by 13
Cell Surface Binding and Internalization of Aβ Modulated by Degree of Aggregation
Bateman, D. A., & Chakrabartty, A. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/962352 · Cited by 14
Stable Isotope Labeling by Amino acid in Vivo (SILAV): a new method to explore protein metabolism
Lehmann, S., Vialaret, J., Gras-Combe, G., Bauchet, L., Hanon, O., Girard, M., Gabelle, A., & Hirtz, C. (2015) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.7289 · Cited by 13
A Translational Systems Pharmacology Model for Aβ Kinetics in Mouse, Monkey, and Human
Karelina, T., Demin, O. O., Nicholas, T., Lu, Y., Duvvuri, S., & Barton, H. A. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12211 · Cited by 13
Guzmán‐Ruiz, M. A., Herrera‐González, A., Jiménez, A., Candelas‐Juárez, A., Quiroga‐Lozano, C., Castillo‐Díaz, C., Orta‐Salazar, E., Organista‐Juárez, D., Díaz-Cintra, S. Y., & Guevara‐Guzmán, R. (2021) · BMC Neuroscience · doi:10.1186/s12868-021-00620-9 · Cited by 14
Aisen, P. S. S. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70091-7 · Cited by 13
Liang, F., Sun, F., He, B., & Wang, J. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.03.043 · Cited by 13
Untangle the mystery behind DS-associated AD – Is APP the main protagonist?
Elangovan, A., Babu, H. W. S., Iyer, M., Gopalakrishnan, A. V., & Vellingiri, B. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101930 · Cited by 12
Multiplexing and multivariate analysis in neurodegeneration
Andréasson, U., Portelius, E., Pannee, J., Zetterberg, H., & Blennow, K. (2012) · Methods · doi:10.1016/j.ymeth.2012.02.004 · Cited by 14
Lambracht‐Washington, D., Fu, M., Wight‐Carter, M., Riegel, M. S., & Rosenberg, R. N. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160947 · Cited by 12
Daurio, N. A., Zhou, H., Chen, Y., Sheth, P. R., Imbriglio, J. E., McLaren, D. G., Tawa, P., Rachdaoui, N., Previs, M. J., Kasumov, T., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00380 · Cited by 12
Morais, G. P., Neto, I. V. D. S., Marafon, B. B., Ropelle, E. R., Cintra, D. E., Pauli, J. R., & da Silva, A. S. R. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.31005 · Cited by 14
Zhang, Q., Liu, J., Hu, X., Wang, W., & Yuan, Z. (2015) · ACS Macro Letters · doi:10.1021/acsmacrolett.5b00033 · Cited by 12
Varma, M. E., Shravage, B. V., Tayade, S. B., Kumbhar, A. S., Butcher, R. J., Jani, V., Sonavane, U., Joshi, R., & Kulkarni, P. P. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130265 · Cited by 11
Aβ31–35 Decreases Neprilysin-Mediated Alzheimer’s Amyloid-β Peptide Degradation
Leite, J. P., Lete, M. G., Fowler, S. A., Gimeno, A., Rocha, J. F., Sousa, S. F., Webster, C. I., Jiménez‐Barbero, J., & Gales, L. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00432 · Cited by 11
Anti-amnesic and Neuroprotective Potential of Genistein Against Alzheimer’s Disease
Singh, N. K., Verma, N. K., Gupta, J. K., & Raghav, J. (2023) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-023-00452-0 · Cited by 12
Yazdi, M. K., Alavi, M. S., & Roohbakhsh, A. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13981 · Cited by 12
Mendonsa, G. R., Zakaria, J. A. D., Lin, A., Vijairania, P., Jong, Y.-J. I., & Baenziger, N. L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004655 · Cited by 16
In Vivo Large-Scale Mapping of Protein Turnover in Human Cerebrospinal Fluid
Lehmann, S., Hirtz, C., Vialaret, J., Ory, M., Gras-Combe, G., Corre, M. L., Badiou, S., Cristol, J., Hanon, O., Cornillot, E., et al. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b03328 · Cited by 11
Schmidt, M. E., Siemers, E., Snyder, P. J., Potter, W. Z., Cole, P. E., & Soares, H. D. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.03.010 · Cited by 11
Janssen, L., Keppens, C., Deyn, P. P. D., & Dam, D. V. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.027 · Cited by 16
Kamble, S. A., Barale, S. S., Dhanavade, M. J., & Sonawane, K. D. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104691 · Cited by 11
Yang, T., Zhang, D., Huang, H., Liu, F., Wu, J., Ma, X., Liu, S., Huang, M., Zhou, Y., & Shen, Y. (2025) · Brain · doi:10.1093/brain/awaf186 · Cited by 12
Targeting tau in Alzheimer’s Disease: rationale, approach and challenges
Aslanyan, A., Foiani, M. S., Giovannucci, T. A., McDade, E., Duff, K., Mummery, C. J., Schöll, M., Wildsmith, K. R., & Paterson, R. W. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00925-5 · Cited by 10
Singh, S. A., Miyosawa, K., & Aikawa, M. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1078731 · Cited by 10
Shobo, A., Röntgen, A., Hancock, M. A., & Multhaup, G. (2022) · FEBS Letters · doi:10.1002/1873-3468.14358 · Cited by 10
Metadata
- Authors
- Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Bateman, Randall J
- Venue
- Nature Medicine
- Published
- 2006-06-25
- Volume
- 12
- Issue
- 7
- Pages
- 856-861
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC2983090
- OpenAlex
- W2171259749
- Cited by
- 599
- References
- 41
- Citations by year
- 2026: 15 · 2025: 32 · 2024: 33 · 2023: 27 · 2022: 19 · 2021: 28 · 2020: 38 · 2019: 34 · 2018: 23 · 2017: 35 · 2016: 36 · 2015: 40 · 2014: 31 · 2013: 30 · 2012: 40
- FWCI
- 16.79
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Eli Lilly and Company
- American Academy of Neurology
- National Institutes of Health (5p41rr000954-34)
- National Institute on Aging (L30 AG024455, K08AG027091, P 50 AG05681, P50AG005681)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 056341, P30DK056341)
- National Center for Research Resources (P41-RR000954, RR-000954, M01-RR00036, M01RR000036)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- amyloid-beta, Alzheimer's disease, cerebrospinal fluid, amyloid precursor protein, biomarkers
- MeSH terms
- Amino Acid Sequence, Humans, Models, Molecular, Molecular Sequence Data, Protein Conformation, Biomarkers, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.